Posted in Policy / Pricing FDA accelerated approval path needs improvement, says ICER April 16, 2026 Pharmaphorum The FDA’s accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER. Policy / PricingRead full story